Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clinical trial results for its seasonal flu vaccine candidate, mRNA-1010, and announced positive Phase 1 data for its hantavirus vaccine.
These 3 Covid-era stocks set up a 2026 comeback as hantavirus revives the pandemic trade and lifts one player 36% off May lows.
MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.
Evercore ISI analysts said in a note they “see no meaningful revenue opportunity” for Moderna in hantaviruses.
Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strategic partnership in the United Kingdom. Management attributed the strong year-over-year growth to international demand for its COVID vaccine products, with CEO Stéphane Bancel noting, “We grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in the U.K.” Despite these g
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.29%. June E-mini S&P futures (ESM26 ) rose +0.18%, and June E-mini Nasdaq futures...
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the
A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.
After facing pressure from the summer of 2021 through the end of 2025, Moderna shares have staged an impressive comeback, rallying roughly 50% from their recent lows as investors return their focus to the biotech sector. The rally also received support following reports of a U.S. national testing positive for Hantavirus, as the company disclosed it is exploring an “early-stage and ongoing” treatment program targeting the disease. With those catalysts, let’s examine the technical setup on the daily and monthly charts.
Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands...
Moderna shares are rallying following a report the company is researching a hantavirus vaccine.
Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including memory chip stocks Micron Technology (MU), Intel (INTC), and Qualcomm (QCOM) opening at record highs; shares of Moderna (MRNA) and Novavax (NVAX) reacting to concerns around the hantavirus; and Constellation Energy (CEG) affirming its full-year guidance after beating first quarter earnings estimates.
Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Stock Market Today: Futures were down while oil prices rose on Iran tensions. Intel, Lumentum, Moderna, Circle Internet are winners..
Moderna rallies 7% on hopes of hantavirus research.
The company confirmed early-stage hantavirus research as a WHO-confirmed outbreak grows, while flu vaccine data published in a top medical journal
Shares of Moderna (NASDAQ:MRNA) climbed nearly 8% in premarket trading on Monday after reports emerged that a U. S.
President rejects Iran’s response, Warsh’s favored inflation measure, airlines are raising bag fees, and more news to start your day.
Moderna jumps after the U.S. health department says a passenger on a repatriation flight tested mildly positive for hantavirus. Moderna says it’s working on an ‘early-stage and ongoing’ treatment for hantavirus.
Investing.com -- Moderna shares jumped nearly 8% in premarket trading on Monday after a U.S. national tested positive for the Andes strain of hantavirus, drawing attention to the company’s early-stage work on a potential hantavirus treatment.
↗️ Moderna (MRNA): Shares jumped 8% premarket after the biomedical company told media outlets that it has been researching vaccines to protect against hantaviruses since before a recent cruise-ship outbreak.
The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.
Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability. But there are ample reasons to avoid buying MRNA stock today.
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population. Regulatory submissions for mRNA-1010 are in progress in the US, Europe, Canada, and Australia, with the US FDA reviewing the data and an approval decision expected later this year. Separately, Moderna advanced its mRNA-based hantavirus vaccine collaboration with Korea University's Vaccine Innovation...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
